Structure, function, and pathology of protein O-glucosyltransferases

Muhammad Zubair Mehboob1 and Minglin Lang1,2

Abstract
Protein O-glucosylation is a crucial form of O-glycosylation, which involves glucose (Glc) addition to a serine residue within a consensus sequence of epidermal growth factor (EGF)-like repeats found in several proteins, including Notch. Glc provides stability to EGF-like repeats, is required for S2 cleavage of Notch, and serves to regulate the trafficking of Notch, crumbs2, and Eyes shut proteins to the cell surface. Genetic and biochemical studies have shown a link between aberrant protein O-glucosylation and human diseases. The main players of protein O-glucosylation, POGLUTs, use uridine diphosphate (UDP)-Glc as a substrate to modify EGF repeats and reside in the endoplasmic reticulum via C-terminal KDEL-like signals. In addition to O-glucosylation activity, POGLUTs can also perform protein O-xylosylation function, i.e., adding xylose (Xyl) from UDP-Xyl; however, both activities rely on residues of EGF repeats, active-site conformations of POGLUTs and sugar substrate concentrations in the ER. Impaired expression of POGLUTs has been associated with initiation and progression of human diseases such as limb-girdle muscular dystrophy, Dowling–Degos disease 4, acute myeloid leukemia, and hepatocytes and pancreatic dysfunction. POGLUTs have been found to alter the expression of cyclin-dependent kinase inhibitors (CDKIs), by affecting Notch or transforming growth factor-β1 signaling, and cause cell proliferation inhibition or induction depending on the particular cell types, which characterizes POGLUT’s cell-dependent dual role. Except for a few downstream elements, the precise mechanisms whereby aberrant protein O-glucosylation causes diseases are largely unknown, leaving behind many questions that need to be addressed. This systemic review comprehensively covers literature to understand the O-glucosyltransferases with a focus on POGLUT1 structure and function, and their role in health and diseases. Moreover, this study also raises unanswered issues for future research in cancer biology, cell communications, muscular diseases, etc.

Facts
- POGLUTs, similar to their Drosophila homolog rumi, add O-Glc to serine residues within the consensus sequences of EGF-like repeats found in several proteins and these repeats are essential for regulating many cellular functions.
- POGLUTs have a CAP10 catalytic domain involved in transferring Glc from UDP-Glc and a KDEL-like terminal signal, necessary for their binding to the KDEL receptors and recycling to the endoplasmic reticulum.
- Despite the glucosyltransferase activity, POGLUTs can also act as xylosyltransferases, i.e., adding Xyl from UDP-Xyl onto a serine residue.
- POGLUTs use both Notch and TGF-β1 pathway to manipulate the expression of CDKIs and, in turn, function in a cell type-dependent manner. Their overexpression increases cell proliferation in some cells, while inhibiting cell growth in other cells.

Correspondence: Minglin Lang (langml@ucas.ac.cn)
1CAS Center for Excellence in Biotic Interactions, College of Life Science, University of Chinese Academy of Sciences, Beijing 100049, China
2College of Life Science, Hebei Agricultural University, Baoding 071001, China
Edited by F. Pentimalli

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Open questions

- Why and how can POGLUT1 display dual functionality, and why is this role cell-type specific?
- Which structural regions are different among the POGLUTs, which urge the modification of distinct sites within an EGF repeat, and why are POGLUT2 and 3 unable to modify POGLUT1 target site?
- Apart from the Notch pathway, what are the other possible pathways targeted by these glucosyltransferases affecting cell proliferation?

Introduction

Glycosylation, a non-templated and common enzymatic modification, involves the addition of glycans to macromolecules and is considered essential for cell viability and cellular responses in both uni- and multicellular organisms. It adds structurally complex glycans assembled mainly by ten monosaccharides and occurs in different cell compartments, such as the cytoplasm and nucleus (intracellular glycosylation), and lumens of the endoplasmic reticulum (ER) and Golgi apparatus (secretory glycosylation; Fig. 1). For secretory glycosylation, one mammalian cell contains over 200 kinds of glycosyltransferases and glycosidases, whereas in the intracellular glycosylation, only O-linked N-acetylgalactosamine transferase (OGT) and N-acetylgalactosaminidase (OGA) are known to modify nuclear and cytosolic proteins. Most of the translated proteins are primarily modified with N-linked glycans, but seven distinct types of O-linked glycans have also been found in humans, based on the first sugar binding to Ser/Thr residue. Except for the cleavage of intact N-linked glycans by endoglycosidases and O-linked N-acetylgalactosamine (O-GlcNAc) by OGA, so far, no additional endoglycosidase for O-glycans has been reported, complicating the study of O-glycans in health and diseases. O-linked glycans are detected either on specific domains with consensus sequences, such as the epidermal growth factor (EGF)-like repeats and thrombospondin type 1 repeats (TSRs) or on collagen repeats present in collagen and adiponectin, in addition to some

![Cellular regulation and representation of glycans](image)
unknown set sequences such as the target site of OGT enzyme\textsuperscript{5}. Apart from O-GlcNAc attachment to proteins in the cytosol and nucleus by OGT, protein modification by glycosyltransferases occurs in the ER and Golgi apparatus, where the addition of sugars takes place progressively.

\textit{O}-glucosylation refers to the addition of glucose (Glc) to EGF-like repeats of diverse substrates, such as coagulation factors VII, IX and protein Z\textsuperscript{7}, Notch receptor and its ligands\textsuperscript{8}, crumbs\textsuperscript{2,9}, Eyes shut (Eys) of \textit{Drosophila}\textsuperscript{10}, etc., some of which have shown impaired function after an aberrant glucosylation occurred. The biological importance of \textit{O}-glucosylation has been highlighted in several cellular processes such as promoting mouse gastrulation by modifying the crumbs\textsuperscript{2} protein\textsuperscript{9}, separating \textit{Drosophila} rhabdomere by acting on Eys protein\textsuperscript{10}, and playing a critical role in skin pigmentation and embryonic development through Notch signaling\textsuperscript{11,12}. In humans, three protein \textit{O}-glucosyltransferases (POGLUT1, 2, and 3) perform \textit{O}-glucosylation activity by using uridine diphosphate (UDP)-Glc as a substrate\textsuperscript{8,13} and their homolog called Rumi performs equivalent function in \textit{Drosophila}\textsuperscript{14}. Alternatively, POGLUT1, 2, and 3 have been named as KTELC1, KDELC2, and KDELC3, respectively. These soluble enzymes accept only properly folded EGF-like repeats by rejecting linear peptides, suggesting that POGLUTs have a role in quality control of EGF-like repeats\textsuperscript{15}. A single EGF-like repeat is a small protein motif with 30–40 AA (frequently repeated) and can vary in numbers from one in coagulation factors to >300 in \textit{Drosophila} Dumpy protein. These repeats are found to be evolu tionarily well conserved in the Notch receptor family and can be modified by \textit{O}-fucosylation\textsuperscript{16,17}, \textit{O}-xylosylation\textsuperscript{18}, and \textit{O}-\textit{N}-acetylglucosamine\textsuperscript{19}, some of which play an important role in animal development\textsuperscript{20}. There is only one Notch receptor in \textit{Drosophila}, whereas humans have four Notch receptors. Both Notch1 and 2 possess 36 EGF repeats compared to Notch3 and 4 with 34 and 29 EGF repeats, respectively. Notch receptors harbor three domains named Notch extracellular domain (NECD), transmembrane domain, and intracellular domain (NICD), and for signaling to occur, ligand binding induces a proteolytic cleavage in the NECD, releasing the NICD to promote the transcription of target genes\textsuperscript{21} (Fig. 2). As the NECD is composed of multiple EGF repeats, post-translational modifications of repeats may affect ligand binding and Notch cleavage. As Notch pathway conserved from \textit{Drosophila} to human involves regulating cell fate

\textbf{Fig. 2 A representation of Notch structure, modification, and signaling.} Notch receptor involved in several biological processes has three domains: NECD, NTD, and NICD. The NECD comprises a set of EGF-like repeats which undergo glycosylation. (1) The properly folded EGF repeats of NECD are modified with glycans added by glycan-specific enzymes and (2) these glycans are further extended in the Golgi apparatus or even also in the ER. (3) Sugar decorated Notch is transported to the cell membrane through membrane-bound vesicles. (4) After ligand (Delta, Jagged) binding, the ADAM proteases and \ensuremath{\gamma}-secretases execute Notch S2 and S3 cleavage, respectively, ultimately releasing the NICD that moves to the nucleus (5) where it binds the Notch pathway effector proteins to induce the expression of Notch target genes.
during animal development, embryonic neurogenesis, cell proliferation, etc.\textsuperscript{21–24} impaired Notch signaling/glucosylation has been implicated in causing human pathologies, such as cerebrovascular disorder, cancer, leukoencephalopathy, etc.\textsuperscript{25–30}.

Mutations in \textit{POGLUT1} have been reported to cause human diseases showing phenotypical symptoms, such as Dowling–Degos disease 4 (DDD4) and limb-girdle muscular dystrophy-21 (LGMDR21), and are involved in reducing O-glucosylation activity on Notch\textsuperscript{31,32}, thereby impairing Notch signaling in muscle and skin development. Furthermore, immunohistochemical staining for POGLUT1 is 50% weaker in DDD4 patients lesional skin compared to controls\textsuperscript{12}, indicating its low expression in POGLUT1 is 50% weaker in DDD4 patients lesional skin impairing Notch signaling in muscle and skin development.

The CAP10 protein was first discovered in \textit{Drosophila} and on the cell surface\textsuperscript{14}, whereas deletion of \textit{POGLUT1} in human embryonic kidney 293 (HEK293T) cells decreased plasma membrane expression of Notch\textsuperscript{13,14}. A recent effort to structurally elaborate the molecular mechanism of POGLUT1, 2, and 3 has tremendously highlighted the key points of O-glucosylation\textsuperscript{34}; however, there is no comprehensive review written by considering their sequence-based structural features and functionality. Concerning the cell-specific dynamic role of POGLUT1, this systematic review focuses on structural domains and dual function of POGLUT1 along with all possible pathways experimentally observed in specific cell types. It also covers a wide range of literature along with suggestions to highlight the causative role of POGLUTs in human diseases.

**Sequence-based structural domains**

\textit{POGLUT}s/\textit{rumi} encoding glucosyltransferases possess a catalytic CAP10 domain and a KDEL-like localization signal. The CAP10 protein was first discovered in a \textit{Cryptococcus neoformans} fungus\textsuperscript{35} and most proteins with CAP10 domain also have an ER-retention signal. BLAST analysis has indicated that POGLUT1 shares a high degree of identity (52%) with Rumi than POGLUT2 (37%) and POGLUT3 (38%), but the latter two proteins have an additional filamin-like domain (Fig. 3a). Out of FLAG-tagged POGLUT1, 2, and 3 constructs introduced into \textit{rumi} mutant flies, only POGLUT1 could rescue the Rumi loss-of-function phenotype, although all three human POGLUTs were highly expressed in flies\textsuperscript{15}. Recently, it has been demonstrated that POGLUT2/3 can add O-Glc to a serine residue within the consensus sequence C\textsuperscript{3–5}-X-N-T-X-G-S-F-X-C\textsuperscript{4} of Notch1 EGF11 and Notch3 EGF10, a site distinct from the consensus sequence C\textsuperscript{3–5}-X-S-X-P/A-C\textsuperscript{2} modified by POGLUT1/Rumi\textsuperscript{13,36}. Hereby, both enzymes are unable to rescue the POGLUT1/Rumi loss-of-function phenotypes.

POGLUT1 encompasses two domains: an N-terminal domain having residues 1–180 and a C-terminal domain comprising residues 182–392, and both domains collectively form a UDP-Glc substrate-binding pocket involved in transferring Glc to EGF-like repeats. These repeats are characterized by six cysteine residues that are adequately spaced to form three disulfide bonds between C\textsuperscript{1–3}, C\textsuperscript{2–4}, and C\textsuperscript{5–6}\textsuperscript{37}, and undergo specific posttranslational modifications by several glucosyltransferases (Fig. 4). Protein O-fucosyltransferase 1 (POFUT1) adds O-fucose (Fuc) to Ser/Thr residues within the C\textsuperscript{2–4} to C\textsuperscript{3–5} (C\textsuperscript{X}:C\textsuperscript{X}:T) of EGF repeats\textsuperscript{38–40}, which is further extended by a Fringe enzyme required for Notch-ligand binding\textsuperscript{17,41}. An O-GlcnAc modification is also added to Ser/Thr residues located between C\textsuperscript{5} and C\textsuperscript{6} (C\textsuperscript{5}-X-G-X-(T/S)-G-X-C\textsuperscript{6}) by EGF domain-specific O-GlcNAc-transferase (EGOT) in \textit{Drosophila}\textsuperscript{19,42–44} and mammals\textsuperscript{45,46}, and contributes to epithelial cell–matrix interactions in \textit{Drosophila}\textsuperscript{43}, together with a role in human development\textsuperscript{47}. POGLUTs and Rumi, unlike other glycosyltransferases that can modify both serine and threonine residues, only glucosylate serine residues in the C\textsuperscript{1–2} motif and structural studies of POGLUT1 provide an explanation that POGLUT1 possesses a catalytic base Asp133 that activates the hydroxyl group of serine, not
threonine, by following an SN2 inversion mechanism\(^4\)\(^8\). When replacing serine, threonine fails to adopt the optimal posture for nucleophilic activation due to steric hindrance\(^4\)\(^8\), underlying the preference for serine over threonine for \(\text{O}^{-}\)-glucosylation.

\(\text{O}^{-}\)-Glc attached by POGLUT1, but not by POGLUT2/3, is extended to a di- or trisaccharide by adding xylose (Xyl); the first Xyl is mediated by \(\alpha_1\)-3xylosyltransferases (GXYLT1 and GXYLT2) and the second Xyl is added to Xyl-Glc-O disaccharide by \(\alpha_1\)-3xylosyltransferase-1 (XXYLT1)\(^4\)\(^9\)\(^\text{50}\). Surprisingly, the first Xyl extension of \(\text{O}^{-}\)-Glc negatively regulates Notch trafficking to the cell membrane\(^5\)\(^1\)–\(^5\)\(^3\) and destabilizes EGF repeats that can be restabilized by the addition of second Xyl\(^5\)\(^3\). Furthermore, Xyl extension also decreases the binding of Notch to and its activation by \(\text{trans}\)-ligand, but not \(\text{cis}\)-ligand, in \(\text{Drosophila}\)\(^5\)\(^4\). These findings explain the role of di-Xyl extension in EGF repeats stability and Notch trafficking.

The catalytic CAP10 domain

Several critical residues of CAP10 domain directly interact with an EGF repeat to facilitate its access to the substrate-binding cleft formed by N- and C-terminal domains of POGLUTs\(^4\)\(^8\). Catalytic CAP10 domain of POGLUT1/Rumi has one WXGG and two DXD-like motifs (containing DME and ERD residues), which are essential for enzymatic activity. Studying POGLUT1' interaction with hF7EGF1, hEGF12, and synthetic EGF (+), Li et al.\(^4\)\(^8\) has explained five hydrogen bonds and three regions of the EGF repeats: \(\text{C}^1\text{C}^2\) loop (glucosylated motif), \(\text{C}^2\text{C}^3\) loop (fucosylation motif), and a patch formed by \(\text{C}^4(-2), \text{C}^6(-1),\) and \(\text{C}^6(-2)\) AA, which provide their accurate positioning for enzyme catalysis. Additional interactions are also formed by two POGLUT1 loops: loop 1 (238–242 AA) that folds over the \(\text{C}^1\text{C}^2\) glucosylated motif and loop 2 (170–181 AA) that interacts with the UDP-Glc and \(\text{C}^2\text{C}^3\) fucosylated motif. The \(\text{C}^1\text{C}^2\) and \(\text{C}^2\text{C}^3\) loop interactions constitute almost 80% of the EGF repeats surface buried in POGLUT1, whereas the remaining 20% is constituted by patch residues. In the glucosylated motif (\(\text{C}^1\text{X}^b\text{S}\text{X}^a\text{P}/\text{AC}^2\)), residues \(\text{X}^b\) and \(\text{C}^2\) form three hydrogen bonds with Gln240 of loop 1 and Ala172 of loop 2 in the POGLUT1-EGF complex, whereas the hydroxyl group of the serine residue forms the fourth hydrogen bond with Asp133, the POGLUT1 catalytic base\(^4\)\(^8\). As the asparagine and serine sidechains at \(\text{X}^b\) position make a strong hydrogen bond with Gln240, POGLUT1 prefers to interact with these two residues than arginine, which partially makes EGF repeats a poor substrate for POGLUT1 as observed in the case of mouse Notch1 EGF27, in which mutation of arginine to asparagine resulted in enhanced POGLUT1 activity\(^1\)\(^5\). The fifth hydrogen bond is developed between the NH group of C2(-2) residue in C2C3 loop and the carbonyl oxygen of POGLUT1 residue Pro178. In addition, notable are the extra interactions made by POGLUT1 Trp174 that is sandwiched between Pro175 and residues of C2C3 motif.
The chemical nature of “X” residues on either side of the serine (C^1X_aSX_bXP/AC^2) can influence the efficiency of O-glucosylation by POGLUT1 as kinetic radioactive assays revealed that positively charged histidine and negatively charged aspartate at X_b position in mouse Notch1 EGF27 and Notch2 EGF16 decreased POGLUT1 activity. The proline of C^1C^2 motif stabilizes the POGLUT1–EGF conformation required to generate hydrogen bonds, so residues bulkier than proline cannot be tolerated at this position. Proline and disulfide bonds at its subsites −2 and +3 enable the C^1C^2 motif (C^1X_aSX_bXP/AC^2) to fold into a U-shaped loop, allowing the serine to penetrate deep into the POGLUT1 cleft. Even a single shift in serine position prevents its O-Glc modification, explaining the significance of serine position. This also suggests that POGLUT1 modifies properly folded EGF repeats by developing multiple bonds. Moreover, the five-membered C^1C^2 motif (POFUT1 target) of hEGF domains also acts as a determinant for POGLUT1 to recognize specific target sequence and variability in motif length can make EGF repeats a poor substrate for POGLUT1 and POFUT1. The patch residue C^(-2) is closely associated with the conserved proline in the C^1C^2 motif and together these two residues make interactions with POGLUT1 residues Met103, Phe104, and Pro105. The latter two residues also develop interactions with variable residues C^(-1) and C^(-2) of the EGF repeats. Although similar in POGLUT1 and Rumi, POGLUT2/3 lacks these interacting residues, proposing their reason for targeting distinct site within EGF repeats.

Multiple sequence alignment of POGLUT1 with Rumi, POGLUT2, and 3 has disclosed the conservation of DXD-like motif in glucosyltransferases and lack of WXGG in the latter two (Fig. 3b). Previously, conserved tryptophan within the WXGG motif was found to be important in assisting substrate modification by creating interaction between the enzyme and UDP-Glc donors. Meanwhile, mutation of the WXGG motif (G169E) in mouse POGLUT1 and equivalent G189E substitution in Rumi were detected to diminish enzyme activity, pointing out an essential role of motif in Glc binding and substrate modification. In addition, the last glycine of WXGG motif (167–170 AA of POGLUT1) lies in loop 2 (170–181) of POGLUT1, of which residues Pro171, Ala172, Try174, and Pro178 assist in the successful transfer of Glc. Although POGLUT2 and 3 have displayed an ability to bind and transfer Glc, but they lack a WXGG motif and other indispensable residues of POGLUT1 loop 2.

The classical metal-coordinating DXD motif is mainly shared by those glycosyltransferases that use nucleoside-diphosphate sugars and may contribute to the catalytic activity of enzymes as a systematic replacement of aspartate with alanine (DDD to ADD) in the Fringe DXD motif was found to abolish the Fringe activity completely. POGLUTs and Rumi are independent of divalent ions for glucosylation activity; thus, DXD-like motifs may involve the interaction of O-Glc with divalent calcium ions bound to the short 5–7 AA spacer between each EGF repeat in the NECD. The Arg218 (conserved in glycosyltransferases) in the second DXD-like motif ERD (217–219) of POGLUT1 and Arg279 coordinate with diphosphate of sugar to stabilize a negatively charged enzyme–substrate complex during the transition state of catalysis. Moreover, expression of mutated Rumi (ERD (236–238) mutated to ERA) in Drosophila partially rescued rumi mutant phenotypes, whereas the ARA substitution of ERD showed too weak phenotypic rescue or complete inactivity, reflecting the indeed requirement of ERD motif for O-glucosylation.

**The ER-retention function of KDEL-like signals**

Protein retention signal is one of two ways for targeting soluble proteins to the ER and KDEL (Lys-Asp-Glu-Leu) is the preferred signal in higher vertebrates, but variants of KDEL motif such as prosite motifs ([KRHQSA]-[DENQT]-E-L) are also known to keep proteins ER resident. These motifs may also assist proteins to perform their functions. Compared with Rumi and POGLUT2 having a classical KDEL signal, POGLUT1 and 3 have the KTEL (Lys-Thr-Glu-Leu) and REEL (Arg-Glu-Glu-Leu) motifs, respectively. By interacting with three KDEL receptors (ERD21, 22, and 23) commonly located in the Golgi complex, soluble proteins with functional KDEL-like motif are retrieved from the Golgi back to the ER lumen via retrograde transport. KDEL receptors show the characteristic pH-dependent binding for KDEL-like motifs as they have shown strong binding in the Golgi at pH 6 and become inactive in the ER at pH 7, resulting in release of proteins. By normalizing the BiFC fluorescence signal for KDEL as 100%, KTEL motif showed a slightly weak binding signal up to 80% for KDEL receptors, whereas REEL exhibited 50% signal for ERD22 and 23, inferring different receptor-binding affinity of retention motifs. Moreover, distinct chemical properties of residues in the KDEL-like motifs may also affect their receptor-binding affinity. These localization signals may also play a particular role in enzyme activity as observed for anterior gradient homolog 2, an enzyme involves promoting cell growth/metastasis, which lost the function when changing its KTEL signal to KDEL. Acar et al. and Takeuchi et al. have explained a significant role of KDEL and KTEL for successful ER-retention of glucosyltransferases, but no study has examined in detail the relationship between the retention signals and glucosylation activity; therefore, the role of KDEL-like signals in POGLUT activities must be explored.

The chemical nature of -5 and -6 AA adjacent to retention signal can also influence the efficient ER
retention of proteins, as various constructs of ERp18 motif (HLEDEL), usually having leucine and histidine at positions -5 and -6, respectively, revealed successful ER retention for constructs (HLEDEL or HAEDEL) comprising histidine or other positively charged residues, such as lysine (KLEDEL) at -6 position. These constructs achieved considerable interactions with ERD receptors compared to secreted constructs (AAEDEL or EDEL) with other residues at the same place. Another construct with leucine at -5 position (ALEDEL) developed weak interactions with ERD22 and 23 and was found prominently in ER-Golgi co-localization, indicating the significance of -5 position for receptor interaction. The presence of leucine at -5 position and the lack of histidine/positively charged residue at -6 of the POGLUT1 motif (MLKTEL) partially explains its low binding affinity for KDEL receptors and efficient ER retention. Taken together, it explains that O-glucosyltransferases with different localization signal motifs may have a different binding affinity for receptors and further experimental studies are needed to unearth the significant role of these motifs in enzymatic activities.

Glucosyltransferase and xylosyltransferase activity

To examine the sugar specificity of mouse POGLUT1 against a variety of sugars using the EGF repeats of human factor VII (hFVII) as an acceptor substrate, it was established that POGLUT1 catalyzes the transfer of sugars from both UDP-Xyl and UDP-Glc. Subsequent studies have produced conclusive evidence of Xyl and Glc utilization by other glucosyltransferases as well. Except for the methoxy group of Glc, both UDP sugars have the same orientation of hydroxyl groups, which facilitate their suitability into the same cleft. Those motifs bearing diserine in consensus sequence (C₁-X-S-S-P/A-C₂) are considered most likely to be a target for O-xylosylation. Because in diserine motif (Ⅸ-O-CASSPC) of hFVII EGF, a complete loss of O-glucosylation, as well as O-xylosylation modification in the S52A mutant and a reduction in O-xylosylation activity towards the S53A mutant were detected compared to wild-type motif. Interestingly, an hFIX EGF repeat (CESNPC) lacking diserine) was also O-glucosylated and O-xylosylated, but it was a poor O-Xyl acceptor, similar to S53A mutant. Using hEGF12 and EGF(+) substrates lacking diserine, it was experimentally demonstrated that both EGFs were xylosylated, but there was a twofold increase in V_max and an approximately twofold decrease in K_m for a hEGF12 mutant (Y₁₅VSPC) having diserine compared to the wild-type target. Thus, unlike O-glucosylation activity, O-xylosylation is sensitive to the adjacent residues surrounding the S and second serine within the O-Glc consensus sequence enhances the efficacy of O-xylosylation. Moreover, two local conformational states of POGLUT1 can likely be responsible for its ability to transfer both Glc and Xyl. In UDP-CH2-Glc-based conformation, the C6-hydroxyl group of Glc simultaneously denotes a hydrogen bond to a β-phosphate oxygen atom and accepts a hydrogen bond from POGLUT1 residue Phe278 to increase the saccharide subsite volume for accommodating the Glc. In the second UDP-containing complex, POGLUT1 binds with UDP-Xyl and allows the C5 (without hydroxyl methyl group) of Xyl to develop similar interactions with Phe278, aligning sugar for S435A attack. Recently, POGLUT2 and 3 have been demonstrated to perform O-xylosylation function on Notch1 EGF11, a domain without diserine residues, but with low efficiency compared to glucosylation. Besides, the relative catalytic efficiencies of both sugars may also depend on the available concentration of both sugars and the physiological conditions in the ER.

Importance of O-glucosylation

Depending on the modification site within an EGF-like repeat, O-glucosylation can regulate Notch trafficking and cleavage, the liberation of NECD, Notch-ligand interactions, and Notch expression at the cell surface. O-glucosylation essentially provides stability to EGF-like repeats and, together with O-fucosylation, it is crucial for full Notch activity. O-glucosylated sites in Drosophila Notch contribute to regulate its signaling especially at high temperature and act as a buffer against temperature-dependent loss of Notch signaling. O-Glc modification between C₁ and C₂ of the EGF motif is critical to regulate Notch cleavage and cell surface expression. As in rumi mutant flies, upregulation and accumulation of cell surface Notch were observed without any interruption of Notch-Delta binding; however, Notch signaling pathway was defective due to impaired S2 cleavage, implying the importance of O-glucosylation in Notch cleavage. Likewise, another study with Poglut1-silenced C2C12 cells corroborated that O-Glc modification does not affect Notch-ligand binding, but can disrupt Notch activity at a step between the ligand binding and S3 cleavage. O-Glc modification generally conforms to the NECD to expose the S2 cleavage site upon ligand binding. Moreover, reduced cell surface expression of Notch1 in POGLUT1 knockout (KO) HEK293T cells, and POGLUT1 and POGLUT1 double KO cells indicate the importance of O-Glc for cell surface expression of Notch. Being at the binding interface between DLL4 ligand and Notch1 receptor, O-Glc modification of S435 between the C₁ and C₂ in human Notch1 EGF11 regulates ligand-induced Notch activation as Takeuchi et al. confirmed that O-Glu on the S₄³₅ position modulates cell surface presentation and DLL1-based activation of Notch1. They found that S435A mutation alone did not show a reduction in Notch activity, but a double mutation of S435A and O-Fuc position on EGF8,
as well as on EGF12 caused a reduction of DLL1-based Notch1 activation. The S435A and EGF8 O-Fuc double mutation disrupted cell surface presentation of Notch1, while both EGF12 O-Fuc and S435A mutations modulated the activity of DLL1 to activate Notch1. O-glycosylation, therefore, confers conformational stability to the NECD to enhance S2 cleavage and can govern ligand-dependent Notch activation if occurs on serine residues between C3 and C4 of the EGF repeats. Furthermore, the recognition of properly folded EGF repeats also explains the quality control function of O-glycosylation enzymes.

**Causative role of POGLUTs in human pathologies**

The association between POGLUTs and human pathologies has been documented in many reports, and their link to the following diseases has been researched to date.

**Recessive LGMDR21**

Muscular dystrophy (MD), a group of disorders comprising 30 different kinds of muscular diseases, is a form of inherited disease characterized by constant breakdown and weakness of skeletal muscles over time. Continuous muscle damage is usually repaired by muscle-specific stem cells (SCs), whose pool is continuously regenerated and maintained in healthy muscles. Notch signaling is one of the main pathways for SCs regeneration, regulation, and quiescence. So far, no primary SCs and Notch defects have been reported in MD; however, mutations of POGLUT1 are implicated in causing LGMDR21. Such mutations generally reduce the enzymatic activity of POGLUT1, resulting in impaired Notch signaling and defective SCs regeneration including proliferation, differentiation, and depletion of SCs pool. For example, a POGLUT1 mutation D233E impaired O-Glc modification on Notch1 and decreased expression of NICD and HES-1, resulting in reduced muscle volume and self-renewal capacity of SCs in LGMDR21 patients than that in controls. Several other mutations (Fig. 5) have also been described in POGLUT1, a few of which decrease its expression and others destabilize it. Immunofluorescence staining and western blotting of muscle biopsies of LGMDR21 patients revealed a reduction of the glycosylated form of α-dystroglycan (hypoglycosylation), Notch1 intracellular domain, and PAX7+ cells (dominant form of SCs in muscles). This study also described that I129T, R98W, C102F, and W308L mutations destabilized the POGLUT1, whereas R183W and Y57C mutations decreased the enzymatic activity as compared with control. In summary, these findings uncover the underlying Notch-dependent pathogenic mechanism of POGLUT1 to cause muscular disorder and explain the importance of O-glycosylation in muscle development.

**Dowling–Degos and Galli–Galli disease**

Besides its role in developmental processes, Notch signaling also plays a vital role in skin homeostasis and regulates the proliferation and differentiation of keratinocytes and melanocytes together with their interactions with each other. Notch-induced abnormal pigmentation of skin has been previously described in the literature; for instance, the ablation of a transcription factor RBP-J (necessary for Notch signaling) in mice resulted in reduced melanoblast numbers within hair follicles, showing irregular pigmentation in the dermal papilla. DDD4 is an autosomal dominant disorder characterized by reticular pigmentation, and was initially explained by Dowling and Freudenthal. Both Galli–Galli (being a variant of DDD4) and DDD4 are characterized by the presence of hyperpigmented macules and papules on the skin.
POGLUT1 shows a strong correlation with papules’ formation as immunohistologic staining for POGLUT1 was weaker in DDD4 patients than healthy controls. Although the molecular mechanism of disease is yet unknown, a study of 13 unrelated DDD4 individuals, including 5 patients previously characterized by Hanneken, determined six mutations (Trp4*, Arg69*, Arg132*, Ser212*, Arg279Trp, and Gly342Glufs*22) in POGLUT1 by whole-exome sequencing, which were involved to cause DDD4.

Later, 17 novel frameshifts, nonsense, and missense mutations were reported, which are represented in Fig. 5. The frameshift and nonsense mutations are likely to result in either truncated protein or nonsense-mediated mRNA decay, while missense mutations reduce POGLUT1 expression or activity. For example, exon trapping analysis of frameshift c.320 + 1 G > C mutation in POGLUT1 revealed a complete skipping of exon 3, resulting in disruption of the functionally important POGLUT1 N-terminal domain. These authors also evaluated the effect of missense mutations on POGLUT1 activity and examined that, unlike Val328Gly mutant that was not detected in culture media and degraded as an unstable form, the secretion level of Arg279Gln mutant was similar to wild-type POGLUT1, but it was enzymatically dysfunctional. As aforementioned, both Arg218 and Arg279 of POGLUT1 are involved in substrate binding, so substitution of these residues may likely decrease POGLUT1 activity and substrate affinity. Moreover, small interfering RNA (siRNA)-mediated knockdown of POGLUT1 in melanocyte-derived cell lineage MZ7-MEL altered mRNA expression of Notch signaling components and enhanced the expression of MITF (microphthalmia-associated transcription factor) and TYR (gene of tyrosinase). MITF is essential for melanocytes development and regulates the expression of TYR needed to convert tyrosine to melanin. Taken together, this data reflect the combined effect of Notch signaling, MITF, and TYR to misdirect melanin deposition leading to hyperpigmented macules across the entire body.

Acute myeloid leukemia and acute lymphoblastic leukemia

Association between abnormal proliferation of blood leukocytes and aberrant O-glucosylation has been demonstrated in recent years, but the underlying mechanism is not yet clear. The first report of POGLUT1 association with acute myeloid leukemia (AML) was by Teng et al. when it was isolated and detected in human AML cells transformed from myelodysplastic syndrome CD34+ cells. Among 12 normal human tissues, high level of POGLUT1 mRNA in both the liver and spleen (organs for normal and extramedullary hematopoiesis) suggest that POGLUT1 seems to participate in the development of blood cells. Subsequently, a higher growth rate of POGLUT1 overexpressed U937 cells (monocytic leukemia cell line) in comparison to cells without exogenous POGLUT1 had confirmed the association of POGLUT1 with AML progression, which might occur by inhibiting the CDKIs through Notch signaling.

Inactivation of p15 and p16 has been observed in AML and acute lymphoblastic leukemia; thus, POGLUT1-associated AML was initially considered p15 or p16 dependent. Even though, this perception was immediately declined when p15 and p16 expression level did not change in POGLUT1-downregulated U937 cells showing proliferation inhibition. As HES-1, a transcription factor in Notch signaling induces cell proliferation by p27 inhibition, another study demonstrated that down-regulation of POGLUT1 in U937 cells inhibited cell proliferation by decreasing HES-1 and accumulated CDK1 p27 to cease cell division. HES-1 is also required to repress p21 and p57 in many tissues; hence, the speculation of cell proliferation by these CDKIs may also be considered. Overall, the basic route of leukemia cell proliferation induced by POGLUT1 is not fully unveiled and should be addressed extensively in future studies.

Hepatic and pancreatic dysfunction

Being an ER-resident protein, POGLUTs expression can also relate to the ER stress response. Hepatocytes and pancreatic β-cells have extensive ability to synthesize and export proteins, so ER stress can alter genes expression in these cells. Interestingly, ELISA assay of patients with hepatic dysfunction reported upregulation of POGLUT2 compared to that in healthy controls. Accordingly, ER stress by tunicamycin in hepatoblastoma HepG2 cells also increased POGLUT2 expression level that induced cell proliferation by decreasing HES-1 and accumulated CDK1 p27 to cease cell division. HES-1 is also required to repress p21 and p57 in many tissues; hence, the speculation of cell proliferation by these CDKIs may also be considered. Several studies have also confirmed an association between ER stress and β-cell dysfunction or type 2 diabetes. Upon exposing β-cell line INS-1 to palmitate, high expression of POGLUT2 appeared, which in turn activated caspase-3-dependent apoptosis. In contrast, POGLUT2 inhibition in INS-1 cells reduced expression of apoptotic factor caspase-3 along with attenuation of ER stress, implying a link between POGLUT2 and β-cell apoptosis. Future research is needed to explore the role of POGLUT2 in regulating the physiological process of hepatocytes and pancreatic cells.

Also, POGLUT1 mutation has been reported in primary biliary cholangitis (PBC), a chronic and progressive autoimmune liver disease induced by disruption of small bile ducts. A single-nucleotide polymorphism (rs2293370: susceptible C-allele) identified at position 3q13.33 through a genome-wide association study increased the expression of POGLUT1, which might be involved in the pathogenesis of PBC, possibly by inducing the Notch pathway.
pathway, as Notch signaling is involved in regulating the development of peripheral immune responses\textsuperscript{94}.

**Cell-dependent dual role of POGLUT1 in inhibiting and promoting cell proliferation**

Presently, the dual function of POGLUT1 affecting cell proliferation has been discussed, which is cell-type specific and very similar to cell-dependent dual function of Notch. For example, overactivation of Notch in small-cell lung cancer (SCLC) cells and endothelialial cells has been shown to promote p21- and p27-dependent cell cycle arrest\textsuperscript{95,96}, whereas the oncogenic role of Notch is identified in lymphoblastic T-cell leukemia and fibroblasts that leads to cancer development\textsuperscript{97,98}. Both down- and upregulation of POGLUT1 have been noticed to alter the expression level of CDKIs by affecting Notch or transforming growth factor-β (TGF-β1) pathway and cause cell proliferation inhibition and induction.

By reducing the expression of POGLUT1, exogenous miR-134 overexpression in human endometrial SCs (HuECSCs) downregulated Notch signaling proteins Notch1 and HES-1, and markedly enhanced p27 concentration to repress HuECSCs multiplication, thereby elucidating the inhibitory role of POGLUT1 in endometrial cancer cells\textsuperscript{99} (Fig. 6a, reverse in the figure). Similarly, downregulated POGLUT1 in colorectal cancer (CRC) cells that showed significantly higher expression of POGLUT1 than noncancerous cells prevented illegitimate CRC cell proliferation\textsuperscript{100}. Further, immunostaining analysis of mouse POGLUT1 in mouse (C57BL6/ model) lungs described its higher expression in alveolar and bronchiolar epithelia along with its two- to threefold elevation in non-SCLC (NSCLC), explaining the association of POGLUT1 with lung cancer\textsuperscript{101}. Consistently, genetic silencing of POGLUT1 in A549 and H23 NSCLC cells caused cell cycle arrest by decreasing the transcript level of Notch effectors HEY1 and HES2\textsuperscript{101}. In contrast, the role of POGLUT1 to increase 293TRex cell proliferation has also been documented, as the downregulation of POGLUT1 by siRNA in 293TRex cells moderately increased cell proliferation compared with a decrease in p21 and p27 level\textsuperscript{102}, explaining that POGLUT1 could also regulate cell cycle progression.

TGF-β1 is the second pathway to be affected by POGLUT1. Several communications have studied the significance of TGF-β1 in CDKIs induction and cell cycle inhibition\textsuperscript{103}. TGF-β1 signaling regulates cellular processes by phosphorylation of SMAD proteins, which bind with coSMAD to act as a transcriptional factor and participate in regulating target gene expression. It was observed in human breast cancer cells BT474 that POGLUT1 overexpression in the presence of TGF-β1 improved cell viability and inhibited p16 upregulation through TGF-β1 pathway, suggesting the involvement of POGLUT1 in BT474 cell proliferation\textsuperscript{104} (Fig. 6b). As TGF-β1 signaling pathway induces p16 expression through phosphorylated Smad3, exogenous POGLUT1 overexpression in BT474 cells reduced the endogenous phosphorylation of Smad3\textsuperscript{104}, leading to TGF-β1 dependent role of POGLUT1 in the BT474 cell cycle. Contrarily, Smad3 also showed high expression and stability in response to POGLUT1 overexpression in 293TRex cells, in which POGLUT1 increased p21 and p27 expression through TGF-β1 and contributed to Smad3 stability via inhibiting its ubiquitin-proteasomal degradation, making

---

**Fig. 6 Partial signaling pathways reported based on specific cell types by POGLUT1 for cell proliferation and inhibition.** Dual role of POGLUT1 in cell cycle progression or suppression is cell-type specific. Up to now, a complete signaling pathway for cell proliferation or inhibition in response to overexpression of POGLUT1 is not fully explained; however, POGLUT1 association with Notch and TGF-β1 signaling pathways has been observed. A) In U937 and endometrial cancer cells, higher expression of POGLUT1 increases Notch signaling and HES-1 level, which in turn decreases P27 level without altering p15 and p16, and induces cell cycle progression or tumorigenesis. B) Evidently, decreased expression level of p16 upon overexpressing POGLUT1 has also been observed, which explains the involvement of more than one signaling route in regulating CDKIs level. Uregulated POGLUT1 reduces Smad3 phosphorylation in breast cancer cells by repressing p16 expression in the presence of TGF-β1, thus promoting BT474 cell proliferation. C) In contrast, overexpression of POGLUT1 in 293TRex cells triggers cell cycle arrest and increases Smad3 protein stability via inhibiting its proteasomal degradation. In fact, POGLUT1 enhances TGF-β1 signaling by modulating Smad3 expression and increases level of CDKIs p27 and p21, which bind with CDKs enzymes to block cell proliferation.
the cells susceptible to TGF-β1 dependent cell cycle arrest\textsuperscript{105} (Fig. 6c). The mechanism of Notch-induced modulation of TGF-β1 has also been discussed which can be considered in future studies\textsuperscript{106,107}. Together, these findings reflect the partially observed pathways used by POGLUT1 for dual functionality, but additional efforts are needed to find the cell-specific role of POGLUT1.

### Conclusion and future perspective

Research into the glyobiology with help of modern genetics and genome engineering technologies has contributed to underscore the important regulatory roles of sugar modifications. As discussed above, the responsible enzymes for O-glycosylation, POGLUTs, modify the consensus sequences within EGF repeats of Notch by adding Glc, which involves the structural and functional characterization of the Notch. Further work in area of Notch glyobiology can be expected by considering the characterization of the Notch. Further work in area of Notch glyobiology can be expected by considering the following questions: how can O-Glc change the configuration of NECD and stabilize the EGF repeats? What is the role of O-Glc in S2 cleavage of Notch activation? Furthermore, it is also necessary to find the relationships of POGLUTs with other human diseases and what are the pathomechanisms behind them. Therefore, it takes a lot of scientific work to ascertain the role of protein O-glycosylation and its exact relationship with human diseases.

### Acknowledgements

We thank Professor Wei Wang for his comments and material support for the manuscript. A special thanks is also for Lilian Uwaleke in improving manuscript. This work was supported by the National Natural Science Foundation of China (31571042, Beijing Municipal Natural Science Foundation (7202129), the Special Fund for University Teachers, and the Institute of Scientific Research Cooperation at the Chinese Academy of Sciences (YSS2018Y00 and KJR2015-011), Key Basic Research Project of Applied Basic Research Program of Hebei Province (18966315D), and One Hundred Outstanding Creative Talents Support Program of Hebei (BR2-218).

### Author contributions

Concept and design: M.L. Writing, review, and revision of manuscript: M.Z.M. and M.L. Display item design: M.Z.M.

### Conflict of interest

The authors declare that they have no conflict of interests.

### Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

### Received: 10 March 2020 Revised: 2 December 2020 Accepted: 3 December 2020

Published online: 12 January 2021

### References

1. Reily, C., Stewart, T. J., Renfrow, M. B. & Novak, J. Glycosylation in health and disease. Nat. Rev. Neuro. 15, 346–366 (2019).
2. Zachara, N., Akimoto, Y. & Hart, G. W. in Essentials of Glycobiology. 3rd edn (Cold Spring Harbor, NY, 2017).
3. Stanley, P. Golgi glycosylation. Cold Spring Hort. Perspect. Biol. 3, a005199 (2011).
4. Hart, G. W. & Akimoto, Y. in Essentials of Glycobiology. 2nd edn (Cold Spring Harbor, NY, 2009).
5. Moremen, K. W., Tiemeyer, M. & Nam, A. V. Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13, 448–462 (2012).
6. O’Donnell, N., Zachara, N., Hart, G. W. & Marsh, J. D. O-glycosylation: adding Glc, which involves the structural and functional characterization of the Notch. Further work in area of Notch glyobiology can be expected by considering the characterization of the Notch. Further work in area of Notch glyobiology can be expected by considering the following questions: how can O-Glc change the conformation of NECD and stabilize the EGF repeats? What is the role of O-Glc in S2 cleavage of Notch activation? Furthermore, it is also necessary to find the relationships of POGLUTs with other human diseases and what are the pathomechanisms behind them. Therefore, it takes a lot of scientific work to ascertain the role of protein O-glycosylation and its exact relationship with human diseases.

7. Hase, S. et al. A new trisaccharide sugar chain linked to a serine residue in bovine blood coagulation factors VII and IX. J. Biochem. 104, 867–868 (1988).
8. Shao, L., Luo, Y., Moloney, D. J. & Haltiwanger, R. S. O-glycosylation of EGF repeats: identification and initial characterization of a UDP-glucose: protein O-glucoysltransferase. Glycobiology 12, 763–770 (2002).
9. Ramkumar, N. et al. Protein O-glycosyltransferase 1 (POGLUT1) promotes mouse gastrulation through modification of the apical polarity protein CRUMBS2. PLoS Genet. 11, e1005551 (2015).
10. Halton, A. R. et al. The protein O-glycosyltransferase Rumi modifies eyes shut to promote rhabdomere separation in Drosophila. PLoS Genet. 10, e1004795 (2014).
11. Fernandez-Valdivia, R. et al. Regulation of mammalian Notch signaling and embryonic development by the protein O-glycosyltransferase Rumi. Development 138, 1925–1934 (2011).
12. Basmanav, F. B. et al. Mutations in POGLUT1, encoding protein O-glycosyltransferase 1, cause autosomal-dominant Dowling-Degos disease. Am. J. Hum. Genet. 94, 135–143 (2014).
13. Takeuchi, H. et al. Two novel protein O-glycosyltransferases that modify sites distinct from POGLUT1 and affect Notch trafficking and signaling. Proc. Natl Acad. Sci. USA 115, E8935–E8942 (2018).
14. Acar, M. et al. Rumi is a CAP10 domain glycosyltransferase that modifies Notch and is required for Notch signaling. Cell 132, 247–258 (2008).
15. Takeuchi, H., Kantharia, J., Sethi, M. K., Bakker, H. & Haltiwanger, R. S. Site-specific O-glycosylation of the epidermal growth factor-like (EGF) repeats of notch: efficiency of glycosylation is affected by proper folding and amino acid sequence of individual EGF repeats. J. Biol. Chem. 287, 33994–33994 (2012).
16. Moloney, D. J. et al. Mammalian Notch1 is modified with two unusual forms of O-linked glycosylation found on epidermal growth factor-like modules. J. Biol. Chem. 275, 9604–9611 (2000).
17. Moloney, D. J. et al. Fringe is a glycosyltransferase that modifies Notch. Nature 406, 369–375 (2000).
18. Takeuchi, H. et al. Rumi functions as both a protein O-glucosyltransferase and a protein O-xyllosyltransferase. Proc. Natl Acad. Sci. USA 108, 16600–16605 (2011).
19. Matsuura, A. et al. O-linked N-acetylglucosamine is present on the extracellular domain of notch receptors. J. Biol. Chem. 283, 35486–35495 (2008).
20. Halton, A. R. & Jafar-Negad, H. The multiple roles of epidermal growth factor repeat O-glycans in animal development. Glyobiology 25, 1027–1042 (2015).
21. Kopan, R. & Ilagan, M. X. G. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137, 216–233 (2009).
22. Aster, J. C. In brief: Notch signalling in health and disease. J. Pathol. 232, 1–3 (2014).
23. Friga, U.-M. & Antas, A. M. Cell and molecular biology of Notch. J. Endocrinol. 194, 459–474 (2007).
24. Fortini, M. E. Notch signaling: the core pathway and its posttranslational regulation. Dev. Cell 16, 633–647 (2009).
25. Li, X. et al. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat. Med. 15, 1289 (2009).
26. Boldo, V., Grego-Bessa, J. & de la Pompa, J. L. Notch signaling in development and cancer. Endocr. Rev. 28, 339–363 (2007).
27. Stanley, P. & Okajima, T. Roles of glycosylation in Notch signaling. Curr. Top. Dev. Biol. 92, 131–164 (2010).
28. Takeuchi, H. & Haltiwanger, R. S. Role of glycosylation of Notch in development. Semin. Cell Dev. Biol. 21, 638–645 (2010).
29. Urata, Y. & Takeuchi, H. Effects of Notch glycosylation on health and diseases. Dev. Growth Differ. 62, 35–48 (2020).
30. Bianchi, S., Dotti, M. T. & Federico, A. Physiology and pathology of notch signalling system. J. Cell Physiol. 207, 300–308 (2006).
31. Servín-Morilla, E. et al. POGlut1 biallelic mutations cause myopathy with reduced satellite cells, α-dystroglycan hypoglycosylation and a distinctive radiological pattern. Acta Neuropathol. 139, 565–582 (2020).
32. Ralser, D. J. et al. Altered Notch signaling in Dowling-Degos disease: additional mutations in POGlut1 and further insights into disease pathogenesis. J. Investig. Dermatol. 139, 960–964 (2018).
33. Takeuchi, H. et al. O-Glycosylation modulates the stability of epidermal growth factor-like repeats and thereby regulates Notch trafficking. J. Biol. Chem. 292, 15964–15973 (2017).
34. Yu, H. & Takeuchi, H. Protein O-glucosylation: another essential role of glucosyltransferase activity of O-fucosyltransferase 1 to Notch signaling. Glycobiology 28, 299 (2009).
35. Lee, T. V. et al. Negative regulation of Notch signaling by xylose. EMBO J. 1107 (2019).
36. Whitworth, G. E., Zandberg, W. F., Clark, T. & Vocadlo, D. J. Mammalian protein O-glucosylation: another essential role of glucosyltransferase activity of O-fucosyltransferase 1 to Notch signaling. Glycobiology 28, 299 (2009).
37. Chang, Y. & Kwon-Chung, K. Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptoccus neoformans. J. Bacteriol. 181, 5636–5643 (1999).
38. Ogawa, M. A new type of O-glucose modification by POGlut2 and POGlut3 controls Notch signaling and trafficking. Trends Glycobiol. Glycotechnol. 31, E53–E54 (2019).
39. Chang, J.-Y., Li, L. & Lai, H. A major kinetic trap for the oxidative folding of N-terminal epidermal growth factor. J. Biol. Chem. 276, 4845–4852 (2001).
40. Luo, Y. & Haltiwanger, R. S. O-fucosylation of notch occurs in the endoplasmic reticulum. J. Biol. Chem. 280, 11289–11294 (2005).
41. Muller, R., Jenny, A. & Stanley, P. The EGF repeat-specific O-GlcNAc-transferase Egot interacts with notch signaling and pyrimidine metabolism pathways in Drosophila. PLoS ONE 8, e62835 (2013).
42. Sakaidani, Y. et al. O-Linked-N-acetylgalactosamine on extracellular protein domains mediates epithelial cell–matrix interactions. Nat. Commun. 2, 1–9 (2011).
43. Ogawa, M., Senoo, Y., Ikeda, K., Takeuchi, H. & Okajima, T. Structural divergence in O-GlcNAc glycans displayed on epidermal growth factor-like repeats of mammalian notch1. Molecules 23, 1745 (2018).
44. Sakaidani, Y. et al. O-Linked-N-acetylgalactosamine modification of mammalian Notch receptors by an atypical O-GlcNAc transferase Egot1. Biochem. Biophys. Res. Commun. 419, 14–19 (2012).
45. Savaguch, S. et al. O-GlcNAc on NOTCH1 EGF repeats regulates ligand-induced Notch signaling and vascular development in mammals. Dev. Cell 6, e2419 (2017).
46. Shaheen, R. et al. Mutations in EOGT confirm the genetic heterogeneity of autosomal-recessive Adams-Oliver syndrome. Am. J. Hum. Genet. 92, 596–604 (2013).
47. Li, Z. et al. Structural basis of Notch O-glycosylation and 0-xylosylation by mammalian protein-O-glycosyltransferase 1 (POGLUT1). J. Biol. Chem. 280, 207–209 (2009).
48. Sethum, K. et al. Molecular cloning of a xylosyltransferase that transfers the second xylose to O-glycosylated epidermal growth factor repeats of notch. J. Biol. Chem. 287, 2739–2748 (2012).
49. Lee, T. V. et al. Negative regulation of Notch signaling by xylose. PLoS Genet. 9, e1003547 (2013).
50. Uzawa, Y. et al. Xylosyl extension of O-glucose glycans on the extracellular domain of NOTCH1 and NOTCH2 regulates Notch cell surface trafficking. Cell 149, 1220 (2020).
51. Matsumoto, K. et al. Dual roles of O-glucose glycans redundant with monosaccharide O-fucose on Notch in Notch trafficking. J. Biol. Chem. 291, 13743–13752 (2016).
52. Lee, T. V., Pandey, A. & Jafar-Nejad, H. Xylosylation of the Notch receptor preserves the balance between its activation by trans-Delta and inhibition by cis-binding ligands in Drosophila. PLoS Genet. 13, e1006723 (2017).
53. Yu, H. et al. Structural analysis of Notch-regulating Rumi reveals basis for pathogenic mutations. Nat. Chem. Biol. 12, 735–740 (2016).
93. Sun, Y. et al. Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-β signaling. Oncogene 24, 5365 (2005).

94. Radvke, F., MacDonald, H. R. & Tacchini-Cottier, F. Regulation of innate and adaptive immunity by Notch. Nat. Rev. Immunol. 13, 427–437 (2013).

95. Situranpong, V. et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res. 61, 3200–3205 (2001).

96. Noseda, M. et al. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol. Cell Biol 24, 8813–8822 (2004).

97. Zlobin, A., Bloodworth, J. C., Baker, A. T. & Otsipo, C. Notch Signaling Pathway in Carcinogenesis (Springer, 2019).

98. Pancewicz, J. et al. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1–associated adult T-cell leukemia. Proc. Natl Acad. Sci. USA 107, 16619–16624 (2010).

99. Gao, Y., Liu, T. & Huang, Y. MicroRNA-134 suppresses endometrial cancer stem cells by targeting POGLUT1 and Notch pathway proteins. FEBS Lett. 589, 207–214 (2015).

100. Fang, H. et al. Human CAP10-like protein 46 kDa gene promotes malignancy in colorectal cancer. OMICS J. Integr. Biol. 21, 266–274 (2017).

101. Chammaa, M. et al. RUMI is a novel negative prognostic marker and therapeutic target in non–small-cell lung cancer. J. Cell Physiol. 233, 9548–9562 (2018).

102. Chu, Q., Liu, L. & Wang, W. Overexpression of hCLP46 enhances Notch activation and regulates cell proliferation in a cell type-dependent manner. Cell Prolif. 46, 254–262 (2013).

103. Gordon, K. J. & Blobe, G. C. Role of transforming growth factor-β superfamily signaling pathways in human disease. Biochim. Biophys. Acta Mol. Basis Dis. 1782, 197–228 (2008).

104. Jin, G. et al. Protein O-glucosyltransferase 1 overexpression downregulates p16 in BT474 human breast cancer cells. Oncol. Lett. 8, 594–600 (2014).

105. Xing, Y. et al. hCLP46 increases Smad3 protein stability via inhibiting its ubiquitin-proteasomal degradation. Protein Cell 6, 767–770 (2015).

106. Masuda, S. et al. Notch1 oncoprotein antagonizes TGF-β/Smad-mediated cell growth suppression via sequestration of coactivator p300. Cancer Sci. 96, 274–282 (2005).

107. Sun, Y. et al. Notch4 intracellular domain binding to Smad3 and inhibition of the TGF-β signaling. Oncogene 24, 5365 (2005).